To capture low-IRT CF cases that evade detection, we have had discussions with other NBS programs in the United States about whether to collect risk factors for CF—such as meconium ileus at birth or maternal CFTR modulator drug exposure during pregnancy—on the bloodspot test request form to initiate molecular testing for CF regardless of IRT result when a risk factor is noted. This evidence concerns the gene CFTR and Meconium ileus.